Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia

Ann Lab Med. 2017 Mar;37(2):177-179. doi: 10.3343/alm.2017.37.2.177.

Authors

Nae Yu¹, Saeam Shin², Jong Rak Choi¹, Yoonjung Kim³, Kyung A Lee⁴

Affiliations

¹ Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
² Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Korea.
³ Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
⁴ Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea. KAL1119@yuhs.ac.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Cytidine Deaminase / genetics*
Cytidine Deaminase / metabolism
Dasatinib / therapeutic use
Disease Progression
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl / genetics
Fusion Proteins, bcr-abl / metabolism
Humans
Imatinib Mesylate / therapeutic use*
In Situ Hybridization, Fluorescence
Karyotype
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Microfilament Proteins / genetics*
Microfilament Proteins / metabolism
Oncogene Proteins / genetics*
Oncogene Proteins / metabolism
Protein Kinase Inhibitors / therapeutic use*

Substances

BCL7A protein, human
BCR-ABL1 fusion protein, human
Microfilament Proteins
Oncogene Proteins
Protein Kinase Inhibitors
Imatinib Mesylate
Fusion Proteins, bcr-abl
Cytidine Deaminase
Dasatinib